Proactive Investors - Run By Investors For Investors

Redx Pharma unveils plans to raise up to £14.9mln to accelerate drug development plans

The proceeds will be used to develop two highly promising cancer drug treatments.
Redx Pharma unveils plans to raise up to £14.9mln to accelerate drug development plans
The cash injection will help accelerate the development effort

Redx Pharma Plc (LON:REDX) has unveiled plans to raise up to £14.9mln that will be used to develop two promising pre-clinical drug candidates.

The bulk of the money will come from a £12mln placing of stock with professional investors.

As part of that institutional round finance house Lanstead Capital is subscribing for shares worth around £4.3mln and will feed back the majority of the proceeds in monthly instalments.

Funds will also come from a smaller open offer tranche that allows existing investors to acquire equity on the same terms as the big City investors.

The shares are being sold for 37.5p each, which is a less than 10% discount to Wednesday’s closing price.

The new cash injection will allow the company to push its highly promising cancer immunotherapy drug through early clinical studies to assess its safety.

Called a Porcupine inhibitor it works by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness.

Kill the stem cells and you have a chance of eradicating the disease completely.

Novartis currently is the only drug major with a Porcupine inhibitor in the clinic.

The funds will also be used to carry out work that will make its Bruton's tyrosine kinase inhibitor “clinic-ready”.

The Redx leukaemia treatment is being developed as a second-generation of compound with fewer side-effects than the market leader Imbruvica (often referred to as Ibrutinib).

Importantly, the company’s drug is targeted at overcoming resistance that patients have developed to the current gold standard drugs.

Why Invest In Redx Pharma Plc? Read More Here

Register here to be notified of future REDX Company articles
View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use